Aldeyra Therapeutics organizes the R&D day on Tuesday March 29, 2022
LEXINGTON, Mass., March 22, 2022–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company that discovers and develops innovative therapies for the treatment of immune-mediated diseases, today announced that it will host a research and development day from 10:00 a.m. to 12:00 p.m. a.m. 30 ET Tuesday, March 29, 2022 in New York City.
Aldeyra will announce early data from Phase 2 proof-of-concept clinical trials of ADX-629, a first-in-class, orally administered RASP modulator in three types of inflammatory diseases, and discuss new indications selected for clinical development.
The event will include presentations from members of Aldeyra’s leadership team and Geoffrey M. Thiele, Ph.D., Umbach Professor of Rheumatology in the Department of Internal Medicine, Division of Rheumatology and Immunology, at the Medical Center from the University of Nebraska.
A live audio webcast and slide presentation will be accessible from the “Investors and Media” section of Aldeyra’s website at https://ir.aldeyra.com/. A replay of the webcast will be available for 90 days after the event.
About Aldeyra Therapeutics
Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immune systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokines, systemic mediators of inflammation known as RASPs (reactive aldehyde species). Reproxalap is undergoing phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in phase 2 proof-of-concept clinical trials in psoriasis, asthma and COVID-19. Our pipeline also includes ADX-2191 (0.8% intravitreal methotrexate), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebookand Twitter.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220321005884/en/
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
Investor & Media:
Sharon Merrill Associates, Inc.